Objective Cigarette smoking has been shown in several studies to induce the metabolism of the cytochrome P4501A2 (CYP1A2) substrates clozapine and olanzapine. The aim of the present study was to investigate the dosedependent effect of cigarette smoking on serum concentrations of these drugs in a naturalistic setting. Methods In 73 schizophrenic patients recruited from psychiatric nursing homes, patient characteristics, smoking habits, drug dosing and serum concentrations of clozapine (n=33) and olanzapine (n=40) were registered. Concentration to dose (C/D) ratios of clozapine and olanzapine in non-smokers and subgroups of smokers were compared. Results Fifty-nine patients (80%) were smokers and these were stratified into the following groups according to smoking habits: 1-6 (n=0), 7-12 (n=13), 13-19 (n=18) and ≥20 (n=28) cigarettes daily. While the mean ratio was twice as high in non-smokers compared to smokers for both drugs (p<0.01), the C/D ratios of clozapine and olanzapine were not significantly different between the subgroups of smokers (p>0.15). Absolute serum concentrations were also higher in non-smokers compared to smokers: 50% for clozapine (p=0.058) and 67% for olanzapine (p<0.01). Conclusion A daily consumption of 7-12 cigarettes is probably sufficient for maximum induction of clozapine and olanzapine metabolism. A 50% lower starting dose of both drugs in non-smokers seems rational to avoid side effects.
Introduction
Clozapine was introduced as an antipsychotic agent in the 1980s [8] . Its affinity for the serotonin 5-HT 2A receptor made clozapine a prototype for other atypical antipsychotics launched in the late 1990s, including olanzapine [22] . Olanzapine was approved in 1996, and is used today in the treatment of both schizophrenia and bipolar disease [21] .
Cytochrome P4501A2 (CYP1A2) is a major enzyme involved in the turnover of clozapine and olanzapine [4, 5, 12] . Cigarette smoking is a potent inducer of CYP1A2 [7, 11, 15, 20] and has been shown to affect serum concentrations of both drugs in several studies [5, 19, 23] . These studies report 40-50% lower dose-adjusted serum concentrations in smokers compared to non-smokers, but the dosedependent effect of smoking on the pharmacokinetics of clozapine and olanzapine has not been investigated.
The majority of schizophrenic patients are smokers [10] , and individual differences in smoking habits emphasize the importance of studying variable cigarette consumption on the pharmacokinetics of clozapine and olanzapine. This information would be of clinical relevance for initial dosing strategies according to smoking habits as well as dose adjustments during smoking cessation. Toxicity of clozapine and olanzapine has been described in several case reports following smoking cessation [3, 11, 25] , and the aim of this study was to investigate the impact of different smoking habits on serum concentrations of clozapine and olanzapine in a population of patients with schizophrenia.
Methods

Subjects
The patient population comprised 73 schizophrenic inpatients (50 males, 23 females) with a mean age of 52 years (SD 9) and mean onset age of psychiatric illness 23 years (SD 7). Patients were recruited from nursing homes (five institutions in Oslo, Norway) to ensure a stable population with respect to medication, compliance and environment. The patients received long-term treatment with clozapine (n=33) or olanzapine (n=40) for, on average, the last 18 months before the study. Doses had been adjusted to individual requirements, but were unchanged for at least 4 weeks prior to the study. Smoking habits were reported by the patients and nursing staff. Smokers were stratified into the following groups: 1-6, 7-12, 13-19 and ≥20 cigarettes daily. None of the patients received treatment with drugs known to inhibit or induce CYP1A2 metabolism. The Norwegian Regional Ethics Committee approved the study. All participants received written and oral information and signed an informed consent.
Sampling and drug analysis
Serum samples were drawn 12-24 h after the last dose intake. Concentrations of clozapine and olanzapine were measured by a high performance liquid chromatography tandem mass spectrometry (LC-MS/MS) method used in routine therapeutic drug monitoring at Department of Psychopharmacology, Diakonhjemmet Hospital, Oslo. Briefly, separations were performed on a C 18 column (3.5 μm, 2.1×100 mm, XTerra) with gradient elution (10-80% acetonitrile in 10 mM ammonium acetate, pH 4.5). The m/z transitions 327→270 (clozapine) and 313→256 (olanzapine) were detected. Retention time was 6.1 min for clozapine and 4.9 min for olanzapine.
Comparisons and statistics C/D ratios were compared in relation to smoking habits for both clozapine and olanzapine. Absolute serum concentrations and daily dosage were also compared in smokers and non-smokers. Statistical evaluations were performed by the Students t test for independent samples and p<0.05 was considered statistically significant. Statistical analyses were performed with the software SPSS version 12.0 (SPSS, Ill. USA).
Results
Fourteen patients (20%) were non-smokers while 59 patients (80%) were smokers. The numbers of patients within the smoking subgroups were: 1-6 cigarettes/day (n=0), 7-12 (n=13), 13-19 (n=18) and ≥20 (n=28). Distribution according to clozapine or olanzapine treatment and gender/age in the different subgroups are listed in Table 1 . Figure 1a ,b shows the clozapine and olanzapine C/D ratios in patients with different smoking habits. There were no significant differences in C/D ratio of clozapine (p>0.15) and olanzapine (p>0.7) between subgroups of smokers. Non-smokers had a two-fold higher C/D ratio compared to the smoking subgroups (Fig. 1a,b) . This was consistent for both clozapine (p<0.05) and olanzapine (p<0.01).
Absolute serum concentrations of clozapine and olanzapine were also higher in non-smokers compared to the smoking subgroups (Fig. 1c,d ). Non-smokers displayed 50% (p=0.058) and 67% (p<0.01) higher serum concentrations than smokers in the clozapine and olanzapine group, respectively. Non-smokers had mean clozapine serum concentration of 2,063 nmol/l (Table 2), which is above the defined therapeutic window for clozapine (1,050-1,850 nmol/l) [2] . There were no significant differences in drug dosing between non-smokers and smokers (p>0.3).
Discussion
This study confirms the significant effect of cigarette smoking on clozapine and olanzapine metabolism. Cigarette smokers had twice as high C/D ratio of clozapine and olanzapine compared to non-smoking patients, which is consistent with previous studies [17, 20, 23] . None of the included patients smoked 1-6 cigarettes per day, but there were no significant differences in C/D ratios between patients smoking 7-12, 13-19 and ≥20 cigarettes daily (Fig. 1a,b) . Moreover, the observed mean C/D ratios for clozapine and olanzapine decreased by less than 10% in the two latter subgroups compared to patients smoking 7-12 cigarettes daily. Thus, a daily consumption of 7-12 cigarettes is probably sufficient for maximum induction of clozapine and olanzapine metabolism.
Therapeutic drug monitoring (TDM) is an important tool in the clinical follow-up of antipsychotic treatment [2] . Information from TDM enables individual dose adjustments over time, but most patients receive standard drug doses when starting treatment. However, knowledge about individual factors that determine the pharmacokinetic variability of a specific drug (e.g., age, sex, genetics and interactions) makes it possible to adjust for these differences when new therapy is initiated. The fact that none of the 59 smokers in the present study smoked less than seven cigarettes daily suggest that this group is not relevant in schizophrenic populations. Regarding the interaction of cigarette smoking with clozapine and olanzapine, our findings therefore indicate that it seems adequate to know whether the patient smokes regularly or not in order to prescribe rational starting doses of these drugs.
A question is whether smokers receive suboptimal doses or non-smokers are overdosed at standard therapeutic doses. As cigarette smokers represent the vast majority of schizophrenic patients [6] , it is likely that this group has dictated the dosing standards of clozapine and olanzapine in dose finding studies during drug development. This is supported by the numerous case reports on toxicity of clozapine and olanzapine in patients that quit smoking [3, 11, 25] . Thus, we anticipate that non-smokers are at higher risk of side effects if treated with standard doses of clozapine and olanzapine, and suggest that the starting dose should be reduced by 50% in this group of patients. A similar, gradual dose reduction should be considered during Non-smokers versus smokers: *Clozapine n.s., olanzapine n.s. **Clozapine p=0.058, olanzapine p=0.004 ***Clozapine p=0.004, olanzapine p=0.001
smoking cessation [23] , but TDM would be helpful in both cases to adjust for individual differences in interaction degree.
Smoking is not the only factor of importance for the pharmacokinetic variability of clozapine and olanzapine. It is reported that females obtain significantly higher concentration per dose of both drugs [14, 24] , and the patient minority of smoking females might therefore be particularly vulnerable to side effects when treated with standard doses. In the present study population, the male:female ratio was 2:1, which is typical for schizophrenic populations [1] . As the ratio differed between the various subgroups (Table 1) , it is a possibility that the results have been biased by differences in gender distribution. However, the consistent findings with clozapine and olanzapine, despite different gender distribution in each subgroup ( Table 1 ), indicate that the potential gender bias is limited in this study.
Genetic and dietary factors could possibly affect the degree of interaction with cigarette smoking. The genetic polymorphism of CYP1A2 has been shown to influence the inducibility of the enzyme [18] , but variable CYP1A2 genotypes do not appear to have a significant effect on the turnover of clozapine [23] . Caffeine is a CYP1A2 substrate that has been reported to modestly elevate serum concentrations of clozapine in a small group of patients [16] . In the present study, differences in CYP1A2 genotypes and caffeine intake may have contributed to the individual variability in interaction degree with cigarette smoking.
The absolute serum concentrations of clozapine and olanzapine were higher in non-smokers compared to cigarette smokers (Table 2) . Seizures, sedation and hypotension are all concentration-dependent side effects of clozapine [9] , and a therapeutic window of 1,050-1,850 nmol/l has been suggested for this drug [2] . Mean serum concentrations in non-smokers were above the therapeutic window for clozapine in the present study, but it should be noticed that this group consisted of only five patients. A therapeutic window is yet to be described for olanzapine, but significantly higher olanzapine serum concentrations in patients with side effects have been reported [13, 20] . The two-fold higher C/D ratios of olanzapine and clozapine were not accompanied by significantly lower doses in non-smokers (Table 2 ). This might indicate that the lack of cigarette-interaction in nonsmokers is not generally adjusted for in clinical practice, potentially affecting side effects in this minority group of patients.
In summary, a daily consumption of 7-12 cigarettes is probably sufficient for maximum induction of clozapine and olanzapine metabolism. A 50% lower starting dose of both drugs in non-smokers seems rational to limit side effects. A similar, gradual dose reduction should be considered during smoking cessation.
